Granted Patent B2

US 12,257,272 · App. 17/694,775 · Granted Mar 25, 2025

Inventor: Joseph E. Kovarik (Englewood, CO)

Assignee: Seed Health, Inc.

A61K35/74A61K31/58A61K31/715A61K38/1709A61K38/1758A61K2035/11

Abstract

Claims (18)

1. A method for reducing the likelihood of developing depression in an individual human being, comprising:

providing in the gut of the individual human being bacteria from a population of beneficial bacteria selected from the group consisting of Coprococcus, Roseburia , and Faecalibacterium prausnitzii;

administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and

reducing bacteria in the gut of the individual selected from the group consisting of Pediococcus, Streptococcus, Enterococcus , and Leuconostoc bacteria.

2. The method of claim 1 , wherein said beneficial bacteria further comprises Akkermansia.

3. The method of claim 1 , wherein said beneficial bacteria are first isolated from a human being's stool.

4. The method of claim 1 , wherein the population of beneficial bacteria produce a level of butyrate sufficient to inhibit biofilm formation of pathogens.

5. The method of claim 1 , wherein the step of reducing the number of bacteria comprises administering an antibiotic.

6. The method of claim 1 , wherein the step of reducing bacteria comprise using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system.

7. The method of claim 1 , wherein the population of beneficial bacteria produce a level of butyrate sufficient to reduce gut inflammation.

8. The method of claim 1 , wherein the beneficial bacteria are encapsulated.

9. The method of claim 1 , wherein the beneficial bacteria are from the individual being treated.

10. The method of claim 1 , wherein said beneficial bacteria are first isolated from a human being's stool.

11. A method for reducing the likelihood of depression in an individual human being, said method comprising: reducing the human being's resident populations of gut microbes prior to administering a therapeutically effective amount of a bacterial formulation comprising Coprococcus ; and providing fructan fiber inulin in an amount sufficient to reduce the pH in the colon of the human being to achieve acidifying of the colon, wherein the bacterial formulation is encapsulated.

12. The method as set forth in claim 11 , wherein said step of reducing the human being's resident populations of gut microbes employs a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system.

13. The method of claim 11 , wherein the human being's resident populations of gut microbes comprise a population of bacteria selected from the group consisting of Pediococcus, Streptococcus, Enterococcus , and Leuconostoc bacteria.

14. The method of claim 11 , wherein the bacterial formulation produces a level of butyrate sufficient to inhibit biofilm formation of pathogens and to reduce gut inflammation.

15. The method of claim 11 , wherein said step of reducing the human being's resident populations of gut microbes comprises reducing the number of bacteria selected from the group consisting of Pediococcus, Streptococcus, Enterococcus , and Leuconostoc bacteria.

Assignments (3)

Continuity (25)

References Cited (400)